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Abstract
Background: Meningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this
serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up
program involving subjects up to 20 years of age. Catch-up was important, not only because it prevented disease in
adolescents and young adults at risk, but also because it decreased transmission of the bacteria, since it was in this
age group where the organism was circulating. Our objective is to develop a new vaccination schedule to achieve
maximum seroprotection in these groups.
Methods: A recent study has provided detailed age-structured information on the seroprotection levels against
MenC in Valencia (Spain), where vaccination is routinely scheduled at 2 months and 6 months, with a booster dose at
18 months of age. A complementary catch-up campaign was also carried out in n for children from 12 months to 19
years of age. Statistical analyses of these data have provided an accurate picture on the evolution of seroprotection in
the last few years.
Results: An agent-based model has been developed to study the future evolution of the seroprotection histogram.
We have shown that the optimum strategy for achieving high protection levels in all infants, toddlers and adolescents
is a change to a 2 months, 12 months and 12 years of age vaccination pattern. If the new schedule were implemented
in January 2014, high-risk subjects between 15-19 years of age would have very low seroprotection for the next 6
years, thereby threatening the program.
Conclusions: High protection levels and a low incidence of meningococcal C disease can be achieved in the future
by means of a cost-free change in vaccination program. However, we recommend a new catch-up program
simultaneous to the change in regular vaccination program.
Keywords: Meningococcal C conjugate vaccines, Seroprotection study, Agent-based modelling, Vaccination
programs
Background
Neisseria meningitidis serogroup C (MenC) was the lead-
ing cause of meningococcal disease in Spain in the late
1990s. Invasive disease was most frequent in infants and
toddlers, and also peaked in adolescents and young adults.
Carriage studies showed it to be this older age group in
which MenC was carried [1,2].
In the year 2000, when a conjugated MenC vaccine
became available, the latter was included in the Spanish
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National Immunization Program with a three-dose sched-
ule at 2, 4, and 6 months, and a catch-up regimen in all
the population up to 19 years of age. The objective of the
catch-up was not only to afford direct protection of the
adolescents but also to decrease carriage and therefore
secure indirect protection of the population. After the
beginning of the vaccination campaigns, the incidence of
meningococcal disease decreased by 87% in Spain [3].
In 2005, a seroprotection study showed the short-term
protection afforded by primovaccination in infants [4],
and therefore a booster dose was added in the second year
of life.
© 2014 Pérez-Breva et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
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There are no accurate data on the coverage of the catch-
up campaign in Spain, which proved different in each of
the 17 Autonomous Communities – thereby rendering the
epidemiology different in different areas of the country
[5]. In Valencia, catch-up coverage was age dependent,
ranging from 67% in the oldest subjects to 87% for sub-
jects under 5 years of age [6]. In 2011, a seroprevalence
study was carried out in Valencia in all age groups from
three years of age. This included 1880 blood samples in
which serum bactericidal assay (SBA) was carried out
using rabbit complement (SBAr) [7]. Amathematical anal-
ysis of these results allowed a reliable protective rating in
Spain, taking into account the differences among subjects
included in the primovaccinated or booster groups and in
the catch-up policy.
The protection conferred by the MenC vaccines is not
long lasting, and in infants and toddlers the immunity
disappears relatively fast [8]. This waning protection can
be studied by the dynamics of the serum bactericidal
assays (SBA). Seroepidemiological studies performed 3 to
6 years after a single dose of MenC vaccine proved that
the percentage of seroprotected individuals (SBA ≥ 1:8)
decreased, and that the loss of protection was faster in
infants than in adolescents. Recently, the United Kingdom
and Spain have considered giving a further booster dose
to adolescents in order to keep the young adults protected
when the subjects that were vaccinated at an early age
reach adulthood [9].
It is expected that unless this is done, the protection in
adolescents will wane dramatically in the next few years
due to different reasons. The seroprotection from the
catch-up campaign conducted more than 10 years ago
is waning, especially in subjects vaccinated at an early
age.
If adolescents and young adults become unprotected,
there is a risk of having a new peak inMenC incidence, not
only in this age group but also in the rest of the Commu-
nity, if the bacteria recirculate again. The development of
an optimum strategy for the immediate future is a press-
ing public health need, and in this context the present
study proposes an agent-based model for developing such
a strategy and evaluating its impact.
Methods
Seroepidemiological study
Blood samples were collected from subjects over three
years of age in different health centers of the province
of Valencia (Spain), with an urban and rural distribu-
tion considered representative of the Community. Some
samples were also collected from the largest hospitals
in Valencia. All subjects or their parents/tutors signed
an informed consent. The study was approved by the
Ethics Committee of the Dirección General de Salud
Pública/CSISP, Valencia. Samples were stored frozen
at −80 °C and sent to the national meningococcal ref-
erence laboratory in Madrid, where SBA using rabbit
complement was performed as described elsewhere [10].
Thirteen groups of subjects were studied, each repre-
senting a vaccination program at different ages: 3-4 years,
5-6 years, 7-8 years, 9-11 years, 12-13 years, 14-16 years,
17-19 years, 20-21 years, 22-29 years, 30-39 years, 40-49
years, 50-59 years, and over 60 years. No children under
three years of age were studied, since the immunity of this
age group could be estimated from the clinical trials and
vaccine coverage.
The MenC vaccination status was reviewed for each
participant in the Vaccine Information System (VIS) of
Valencia [11].
Estimation of waning immunity
Linking the seroprotection data to the patient vaccine sta-
tus in the VIS, we were able to plot an evolutive seropro-
tection curve. We considered seroprotection when SBA≥
1:8. Subjects were vaccinated at different ages and with
different schedules, all of which were taken into consid-
eration. The vaccine trademark was very closely related
to the age groups and schedules; consequently, no differ-
ences among the vaccines used in Valencia were taken into
account.
Agent-basedmodel
We developed an agent-based model to simulate the evo-
lution of the seroprotection histogram for the different
age groups in the future, with the current vaccination
schedule and with modified schedules. Our objective was
to establish the best strategy based on two criteria: (i)
seroprotection levels of infants and toddlers under two
years of age are over 60%; and (ii) seroprotection levels
of adolescents between 10-19 years of age are as high as
possible.
We considered one million individuals represented by
nodes and distributed according to the demographic data
for the Community of Valencia [12]. The underlying
demographic model was simulated in such a way that
the total population remained constant: (i) individuals
grew older according to the time-step used in the com-
puter simulation (every step corresponding to one month
in real time); (ii) a fraction of individuals died accord-
ing to the mortality rate corresponding to their age; and
(iii) deceased individuals were replaced by unprotected
newborn infants.
Seroprotection of the individuals (SBA ≥ 1:8) was a
logical variable which evolved stochastically, i.e., after vac-
cination the individuals lose their immunity with a proba-
bility given by the seroprotection curve in Figure 1. Thus,
we had to take into account the age at which the individ-
ual at a given node was vaccinated, because the waning of
seroprotection depends upon the moment of vaccination.
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Figure 1 Plot displaying the fitted seroprotection levels in terms
of age at the time of vaccination and age at the time of
serological study.
This variable was also stored by the computer program.
Newborn infants were assumed to be unprotected.
Age groups were distributed in the same way as in the
seroepidemiological study.
The model proceeded as follows: To provide a sta-
ble demographic state, we assigned an age to each node
according to the population histogram of the Community
of Valencia. Taking into account the mortality rate per age
group, we evolved this situation for a long enough time
until the population histogram remained stable. Coher-
ent mortality rates required that the final population state
should not deviate significantly from the present state,
as is in fact the case. Once the demographic model was
established, we assigned the seroprotection label accord-
ing to the study. A percentage of nodes were labeled as
protected according to the fraction of protected individu-
als found in the seroprevalence study. When an individual
was vaccinated, he or she became seroprotected (we did
not consider vaccination failures). The initial state was
known because we could classify the individuals accord-
ing to their vaccination status (primovaccinated, booster
or catch-up) and the time elapsed from the last vaccine
dose. Starting with this initial condition, we took into
account that with each time-step, each individual loses
his or her immunity according to the decaying probabil-
ity distributions shown in Figure 1, depending on the age
at the time of the last vaccination. For each individual we
also checked whether he or she was vaccinated in a sched-
uled vaccination campaign, and set the vaccination clock
to zero in order to follow the evolution of seroprotection
in the future.
An important point is the natural immunity of the
unvaccinated population. A fraction of unvaccinated indi-
viduals was found to be protected, and this fraction
increased with age. Consequently, in themodel we consid-
ered this constant fraction (Table 1) to be protected and
not to develop meningococcal C disease.
The seroprotection of the vaccinated population never
drops below the natural immunity levels in Table 1,
assuming that the natural immunity is constant over time.
Results and discussion
WaningMenC seroprotection
The seroprotection study provided a snapshot of antibody
persistence in the Valencian population in 2011 based on
the VIS. We fitted an evolutive curve for seroprotection
levels. Individuals with SBA≥1:8 were considered protec-
ted against Neisseria meningitidis C disease. Since early
studies, it has been known that SBA levels decrease very
fast for children, but persist for longer times in adolescents
[8]. The most recent study supports these early results
and clearly shows that seroprotection wanes slower as the
age of the vaccinated individual increases. A remarkable
difference has also been observed between primovacci-
nated subjects (children under one year of age) and those
individuals who received from 2006 a booster dose.
Figure 1 shows the results of the fitting procedure.
The vertical axis represents the percentage of protected
individuals, while the horizontal axis corresponds to the
age at the time of the SBA assay. The vaccination age
is also shown on the top horizontal axis. This fit was
obtained by assuming that 100% (maximum) seroprotec-
tion is achieved at the time of vaccination and persists for
the first year after vaccination (one year being our time
discretization for this study). A large goodness of fit was
obtained with an exponential decay fitting. Further details
Table 1 Fraction of unvaccinated individualswith
SBA ≥ 1 : 8 as a function of age group [13]
Age-group % Seroprotection CI 95%
3-4 years 2.0% [0.1%, 5.8%]
5-6 years 4.0% [0.7%, 8.2%]
7-8 years 5.6% [2.1%, 9.8%]
9-11 years 6.6% [2.9%, 11.0%]
12-13 years 8.2% [4.0%, 12.6%]
14-16 years 9.6% [5.2%, 14.3%]
17-19 years 11.0% [6.4%, 15.6%]
20-21 years 12.3% [7.8%, 16.8%]
22-29 years 13.7% [9.4%, 18.0%]
30-39 years 15.2% [11.4%, 19.2%]
40-49 years 16.2% [12.3%, 20.5%]
50-59 years 18.1% [13.5%, 23.3%]
≥ 60 years 26.6% [20.2%, 34.1%]
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are given in the complementary material on the project
webpage [13].
Vaccination seroprotection wanes very fast for children
under one year of age, while among children fromone year
to 16 years of age the seroprotection period is considerably
larger and increases steadily with age.
Thus, we should distinguish infants (in whom any dose
should be regarded as primovaccination) and children
older than one year (in whom any dose is a booster dose or
catch-up). For example, in children who received a MenC
vaccine dose at 6 months, seroprotection levels (initially
above 90%) decreased to below 50% only 10 months later.
In contrast, in children vaccinated at one year of age, sero-
protection persisted above 50% during at least four years.
The seroprotection half-life was 7 years when the age at
vaccination was 8 years old [13].
Outcome of the present 2-6-18 months MenC vaccination
strategy
The seroprotection status in 2011 is shown in Figure 2. A
broad seroprotection peak, over 50% in the those between
17 and 21 years of age, is a consequence of the catch-
up program carried out from 2002 to 2004, when a large
proportion of subjects between 6-19 years of age were
vaccinated. Children under 3-4 years of age were also rel-
atively well protected as a consequence of the booster
dose in the second year of life. With the present vac-
cine schedule, at 2, 6 and 18 months of life, the predicted
seroprotection level by age group in 2015 shows that the
adolescents will become mostly unprotected, resembling
the prevaccination situation. This is a consequence of
increasing age and waning immunity.
Strategy optimization
A public health goal is to keep adolescents and young
adults well protected without lowering protection among
those under four years of age. In order to optimize the
seroprotection status, it might be desirable to change the
vaccination schedule. To assess this issue, we considered
that vaccines should be given on occasion of the pedi-
atric monitoring visits recommended in the Community
of Valencia (at 15 days, 1, 2, 4, 6 and 12 months of age,
at 15 months and 18 months in the second year of life,
and at 6, 12 and 14 years of age). Taking into account that
such vaccination is not recommended below two months
of age, we combined all the pediatric visits to define all
the possible vaccination schedules with 1, 2 and 3 doses.
This implied 129 different schedules. All of them were
included in the model and simulated, starting in January
2014 and ending in November 2050. For each schedule we
calculated the average protection for infants, toddlers (1-
2 years of age) and teenagers between 10 and 19 years of
age.
The four schedules that obtained the largest seropro-
tection level in each of the three time intervals are rep-
resented in Table 2. The three-dose schedule at 2 and 12
months of life and 12 years of age obtained the highest
seroprotection level in the three age groups that were the
objective of the highest seroprotection.
In relation to a change in vaccination schedule with a
single priming dose in infants under one year of age, it
should be noted that a very recent study clearly shows a
single-dose priming vaccination to be a valuable and rea-
sonable alternative to the current two-dose vaccination
schedule [14].
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Figure 2 Percentage of protected individuals in 2011 (circles) and October 2015 (triangles). The squares correspond to the natural protection
of unvaccinated individuals. The horizontal axis indicates the age group in years.
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Table 2 Best vaccination schedules
Order Schedule Avg. protect. Avg. protect. Avg. protect.
0 y.o. 1 y.o. 10-19 y.o.
1 2, 12, 144 63.84% 95.03% 62.62%
months
2 4, 12, 144 54.45% 95.03% 62.66%
months
3 2, 15, 168 63.80% 82.43% 55.18%
months
4 2, 15, 144 63.81% 82.41% 62.65%
months
The first column is the order. The second is the vaccination schedule. The third is
the average protection of children less than a year old during the period
January, 2014 (new vaccination schedule starts) until November, 2050. The
fourth and the fifth show the same for one year old children and 10-19 years old
adolescents, respectively.
Figure 3 depicts the evolution of the seroprotection
histogram with the best strategy. In the long term, this
strategy achieves the highest protection levels for every
age group.
However, before achieving this result, a transient sit-
uation is observed in which adolescents are poorly pro-
tected. In particular, we can see that in January 2016 (only
two years after starting the new vaccination schedule), the
14-16 year-old subjects are practically at levels of natural
immunity. The reason for this behaviour is that boost-
ing 12 year-olds have still not reached the 14-16 years of
age group, while adolescents show a waning of their SBA
levels.
Complementary catch-up
To overcome this situation, even with a new booster dose
at 12 years of age, there might be a need to perform
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Figure 3 Percentage of protected individuals with the 2-12-144
months strategy. The circles are the result of the seroprevalence
study in 2011, squares correspond to natural immunity, upward
triangles reflect seroprotection in January 2016 (two years after
implementation of the new strategy), and the downward triangles
correspond to the long-term protection achieved in September 2040.
a catch-up program together with the booster. The tar-
get population for the catch-up at least should comprise
subjects aged 13-15 years in January 2014.
In order to maintain good indirect protection, the
objective of the catch-up could not be reaching the
whole population.We therefore considered three different
catch-up scenarios, of different intensity, targeting these
age groups. The results are shown in Figure 4. Even with a
30% catch-up coverage, a very significant improvement in
protection of the 14-16 year-old group is obtained. In this
case the protection by January 2016 (just two years after
starting the new schedule) is around 40%, compared with
10% in the absence of any catch-up campaign. In the long
run, the protection histogram will be the same as that in
Figure 2 for September 2040.
Conclusions
In this study we considered the scenario following a
vaccination schedule change in Spain in the near future.
A snapshot of the seroprotection levels for different
age groups in the Autonomous Community of Valencia
(Spain) was obtained in a seroepidemiological study
carried out in 2011. By crossing these data with the
vaccination records, this detailed study allowed us to
fit an accurate waning seroprotection table for conju-
gate meningococcal C vaccination. This study is not
only important for public health decisions in the imme-
diate future in Spain [15] but also for other countries
which have shifted from polysaccharide to conjugate
vaccination in the last decade [16-18]. Nowadays, the
situation referred to seroprotection in the Autonomous
Figure 4 Percentage of protected individuals with the 2-12-144
months strategy and a catch-up program targeting the 13-15
year-old subjects from January 2014 to December 2014. The solid
line is the protection histogram in January 2016 without catch-up, the
dotted line correspond to the result with a catch-up targeting 30% of
the population in that group, the dashed line stands for 40%, and the
dashed-dotted line stands for 50%.
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Community of Valencia can be considered very good,
as reflected by the rareness of cases of meningococcal C
disease. The explanation for this effective control can be
found in the high serum bactericidal antibody levels in
both adolescents and children under four years of age.
High SBA levels in adolescents from Valencia in 2011 are
the direct consequence of a high coverage catch-up cam-
paign carried out in 2000-2004, in which subjects from
one year to 20 years of age were targeted.
Although MenC disease is now rare in Valencia, the
waning of SBA levels in the near future, especially in
the adolescent population, may imply the recirculation
of MenC. We have quantitatively shown that the 14-16
years age group will become at high risk of contracting
meningococcal disease in 2016, compared with the pre-
vaccination era incidence. This situation has motivated a
plan for changing the vaccination schedule from the three
doses administered at 2, 6 and 18months of age to another
schedule in which one of these doses is removed and dis-
placed to late childhood (some moment between 11 and
14 years of age). This optimization problem can be dis-
cussed in the framework of an agent-based model, and
the best strategy can be defined and selected according to
the levels of protection for adolescents and children rang-
ing from newborn infants to two-year-old toddlers. We
sought a strategy protecting the adolescents from 10 to 19
years of age with a minimum average of 50%, while at the
same time keeping infants with seroprotection levels as
high as possible.
Checking all possible combinations for three doses, we
found the optimum strategy to correspond to vaccination
at 2 months, 12 months and 12 years of age. With this
strategy, infants are protected (with 50% probability) for
at least 5 years. A second booster dose for 12 year-olds
protects them during the adolescence period. Moreover,
this booster dose could be planned easily because, at that
age, the penultimate pediatric monitoring visit is sched-
uled in Spain. The simulation shows that the protection
levels after several decades will rise to levels above the
2011 histogram for all the target groups.
However, that change in schedule will not be fully effec-
tive in the first years, since adolescents from 15 to 19
years of age keep waning their seroprotection, and will
not be included in the booster campaign. With only a
20% seroprotection level in this age group in 2016-2019,
recirculation of MenC in the community could occur. The
model therefore anticipates that the change in vaccination
schedule should be accompanied by a catch-up campaign
in adolescents from 13 to 15 years of age.
It should be mentioned that the model has some limi-
tations. We considered that a booster dose in adolescents
would protect these subjects for the same time period
as primovaccination given at the same age. However, the
serological response could be different, though only an
unexpected short duration of immunity would affect the
model. We also considered that catch-up would be given
in a random fashion. However, it is possible that unvacci-
nated collectivities might appear, with an unknown effect
upon the recirculation of MenC.
The percentage of the population thatmust be protected
in order to prevent MenC circulation is not clear. Trot-
ter et al. [19] postulated that protection would occur with
an immunization threshold in the range of 17 − 26%; this
is the reason why we consider than even a low cover-
age catch-up campaign would be efficacious. The model
allowed us to estimate the minimal vaccination coverage
in the catch-up campaign.
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